Wolfgang Schrader

University of Würzburg — Germany

Medicine · Health Sciences

15h-index577citations57works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Intraocular Surgery and Lenses(18), Retinal Diseases and Treatments(16), Traumatic Ocular and Foreign Body Injuries(15), Retinal and Optic Conditions(12), Retinal and Macular Surgery(11)

Publications57 total

Equipment Knowledge “What Does a Surgeon Need to Know?”
2025
Emergency Vitrectomy for Beginners in Endophthalmitis—The Core Vitrectomy
2025
Gerätekunde „Was muss ein Operateur wissen?“
2023
Notfallvitrektomie für Einsteiger bei Endophthalmitis – die Core-Vitrektomie
2023
Globe and Adnexal Trauma Terminology Survey
JAMA Ophthalmology·2022· 19 citedOpen Access
Augenärztliche Differenzialdiagnose
2021
Diagnostik und Akuttherapie von Augenverletzungen durch Feuerwerkskörper
Der Ophthalmologe·2019· 6 cited
International Practice Patterns for the Management of Acute Postsurgical and Postintravitreal Injection Endophthalmitis
Ophthalmology Retina·2019· 45 citedOpen Access
Agujero Macular Traumático: Aspectos y Controversias
Highlights of Vitreoretina·2019
Prophylactic chorioretinectomy for eye injuries with high proliferative‐vitreoretinopathy risk
Clinical Anatomy·2017· 29 cited
How bad are the long term results under real life conditions beyond 2 years of treatment for wet AMD with ranibizumab or bevacizumab? Results from a 4 year follow up of 77 patients
Investigative Ophthalmology & Visual Science·2013
2030 The Number Of Intravitreal Injections (ivi) Needed Beyond 2 Years Of Treatment For Wet Amd With Ranibizumab Or Bevacizumab Cannot Be Predicted By The Injection Frequency In The 1st Year Of Treatment
SciVee·2012
Long Term Results After Pars Plana Vitrectomy For Terson’s Syndrome
Investigative Ophthalmology & Visual Science·2011
Prognostische Faktoren beim chronisch-diabetischen Makulaödem nach intravitrealer Therapie
Klinische Monatsblätter für Augenheilkunde·2010· 5 cited
Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system
Clinical Therapeutics·2010· 30 cited
Risks and sequelae of scleral perforation during peribulbar or retrobulbar anesthesia
Journal of Cataract & Refractive Surgery·2010· 46 cited
Preservation of Functional Benefit of Loading Dose and Long-Term Visual Outcome After 4-Weekly Injection of Ranibizumab versus 8-Weekly Injection of Bevacizumab for Wet Amd
Investigative Ophthalmology & Visual Science·2010· 1 cited
The options to minimize the surgical trauma to treat ocular diabetic complications and to improve postoperative recovery and quality of life require an individualized approach
The EPMA Journal·2010· 6 citedOpen Access
Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion in a Pair-Matched Analysis
Ophthalmologica·2010· 35 cited
Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – A Matched-Pairs Analysis
Ophthalmologica·2009· 17 cited
page 1 of 3Next →

Frequent Co-authors

Rainer Guthoff(5), Tatjana Josifova(4), Ferenc Kuhn(4), Anja Viestenz(4), Arne Viestenz(4), Marc Schargus(3), Kathrin Hennemann(3), Frank G. Holz(3), Anselm Kampik(3), Bettina Lieb(3), Guntram Kommerell(3), Mariano Irós(2), Meireles Angelina(2), Pietras-Trzpiel Malgorzata(2), Thomas Meigen(2), Christoph Hirneiß(2), Bernhard Schräder(2), W. Behrens‐Baumann(2), E. Gramer(2), Bhartendu Shukla(2)